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ABSTRACT
Dyskeratosis congenita (DKC) is associated with impaired telomere maintenance 
and with clinical features of premature aging. In this study, we analysed global DNA 
methylation (DNAm) profiles of DKC patients. Age-associated DNAm changes were not 
generally accelerated in DKC, but there were significant differences to DNAm patterns 
of healthy controls, particularly in CpG sites related to an internal promoter region 
of PR domain containing 8 (PRDM8). Notably, the same genomic region was also 
hypermethylated in aplastic anemia (AA) – another bone marrow failure syndrome. 
Site-specific analysis of DNAm level in PRDM8 with pyrosequencing and MassARRAY 
validated aberrant hypermethylation in 11 DKC patients and 27 AA patients. Telomere 
length, measured by flow-FISH, did not directly correlate with DNAm in PRDM8. 
Therefore the two methods may be complementary to also identify patients with 
still normal telomere length. In conclusion, blood of DKC patients reveals aberrant 
DNAm patterns, albeit age-associated DNAm patterns are not generally accelerated. 
Aberrant hypermethylation is particularly observed in PRDM8 and this may support 
identification and classification of bone marrow failure syndromes.
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INTRODUCTION
Dyskeratosis congenita (DKC) is a rare disease 
that is often associated with mutations in genes required 
for proper telomere maintenance (e.g. DKC1, TERT, 
RTEL1, TIN2, TERC) [1, 2]. It was the first disease linked 
to short telomeres [3]. Clinically, DKC usually reflects 
a triad of oral leukoplakia, nail dystrophy, and skin 
hyperpigmentation. Other typical manifestations include 
symptoms of bone marrow failure, and fibrosis of lung 
and liver [4]. Diagnosis of DKC necessitates awareness 
in the clinic, but also appropriate laboratory testing of 
telomere length (TL; usually below the 1% percentile) 
and genetic sequencing [5, 6]. However, not all DKC 
patients reveal dramatically shortened telomeres [7] and 
clinically relevant mutations are not always to be found 
[8]. Acquired aplastic anemia (AA) is another bone 
marrow failure syndrome that is likewise characterized by 
telomere attrition [4, 9]. Correct diagnosis of DKC and 
AA is important for adequate treatment and more specific 
biomarkers are urgently wanted [4]. The advances in 
epigenetic profiling methods provide new perspectives for 
biomarkers development [10]. Specific DNA methylation 
(DNAm) changes are indicative for diagnosis, prognosis, 
choice of therapeutic regimen in many diseases [11]. In 
this study, we analyzed DNAm profiles of DKC patients 
to further clarify if age-associated DNAm changes are 
enhanced in this disease [12] and if aberrant DNAm 
patterns can be used to support diagnosis of DKC.
RESULTS AND DISCUSSION
Global DNAm profiles of peripheral blood 
of four DKC patients were analyzed by Illumina 
HumanMethylation450 BeadChip technology. We 
utilized two models for epigenetic age-predictions: a 
Figure 1: Epigenetic age-predictions of DKC samples. Biological age was estimated in DNAm profiles of four DKC samples 
(red; whole blood) and healthy control samples (blue; here 14 samples are exemplarily depicted from GSE32148) [33] using a model 
for epigenetic age-predictions by Horvath A. [13], or our previously published model based on 99 age-associated CpGs B. [12, 14][46]. 
The mean absolute deviation of predicted and chronological age (MAD) is indicated for the control samples. Heatmaps of the 353 age-
associated CpGs of the Horvath model C. and the 99 age-related CpGs of our age-prediction model D. demonstrate similar DNAm patterns 
of DKCs patients and controls. Although DKC is considered to be a premature aging syndrome these broader signatures did not reveal the 
epigenetic age-acceleration in DKC that we previously described for three age-associated CpGs [12]. 
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model developed by Horvath that is based on DNAm 
at 353 age-associated CpG dinucleotides [13], and our 
previously published model based on 99 age-associated 
CpGs [12, 14][]. Overall, the epigenetic age-predictions 
did not demonstrate general acceleration of age-associated 
DNAm (Figure 1). This was unexpected, as we previously 
observed overestimation of biological age using an 
epigenetic signature based on only three age-associated 
CpG sites [12]. This discrepancy may partly be attributed 
to the fact that the linear model for the three-CpG-
Signature has not been specifically trained for young 
donors and to the possibility that only specific CpGs 
reveal aberrant DNAm in DKC. Genes that are frequently 
mutated in DKC (such as DKC1, TINF2, TERT, TERC, 
and RTEL1) did not reflect aberrant DNAm patterns 
(Supplemental Figure 1). 
Comparison of DNAm profiles with four age and 
gender matched controls revealed 764 hypo- and 1,369 
hypermethylated CpGs in DKC (adjusted P value < 0.05; 
Supplemental Table 1). Hypermethylated CpGs were 
highly significantly enriched in promoter regions and 
CpG islands (Supplemental Figure 2). These results led 
Figure 2: Dyskeratosis congenita is associated with hypermethylation in PRDM8. A. Scatter plots of mean DNAm levels 
(four DKC patients as compared to four age and gender matched controls) depict 764 hypo- and 1,369 hyper-methylated CpGs in DKC 
(adjusted P value < 0.05; relevant CpGs of PRDM8 are indicated in red). B. DNAm levels (beta-values) of CpGs associated with PRDM8 
reflect hypermethylation at an internal promoter region in DKC patients (as compared to DNAm profiles of normal blood). The positions 
of two relevant CpGs are indicated (cg19409579 and cg27242132). C. Boxplots represent distributions of beta-values at cg27242132 in 
four DKC samples and 4,131 DNAm profiles of blood samples of 16 different studies (see also supplemental Figure 3). The 99 percentile 
of controls is indicated as dotted line (DNAm level of 52%). D. Quantitative RT-PCR reveals moderate down-regulation of PRDM8 
expression in DKC patients (n = 5; two-sided Student’s t-test; P = 0.0197). E. MassARRAY analysis of DNAm at cg27242132 (PRDM8) 
revealed consistent DNAm levels in neighboring CpGs (controls: n = 10; AA: n = 27; DKC: n = 11). F. In comparison to normal controls the 
DNAm levels at the CpG site cg27242132 were significantly higher in AA (P = 1.49E-05) and particularly in DKC patients (P = 2.51E-06).
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us to the assumption, that specific DNAm patterns can be 
used to support diagnosis of DKC. Therefore, we focused 
on CpGs with a difference in mean DNAm levels of at 
least 30%: 26 CpGs reached this cutoff including five in 
the gene PR domain containing 8 (PRDM8) and two in 
PRDM16 (Figure 2A, Supplemental Table 2). It has been 
demonstrated that PRDM8 is implicated in axon outgrowth 
[15, 16] and regulation of testis steroidogenesis in mice 
[17] - but hardly anything is known about its potential 
role in blood formation. In contrast, PRDM16 is involved 
in human leukemic translocations and was shown to be 
a physiologic regulator of hematopoietic stem cells [18-
20]. Notably, PRDM8 and PRDM16 comprise zinc finger 
motifs as well as PR domains with methyltransferase 
activity (H3K9) [16, 17] making them potential epigenetic 
modifiers of the histone code.
Hypermethylation in PRDM8 was particularly 
observed at the CpG sites cg27242132 and cg19409579 
corresponding to an internal gene region that was hardly 
methylated in DNAm profiles of normal blood (analyzed 
in 4,131 DNAm profiles; Figure 2B and 2C). DNAm 
levels at this region were rather independent from donor 
age (R2 = 0.0311; Supplemental Figure 3), whereas the 
cellular composition may be relevant as PRDM8 is slightly 
higher methylated in lymphocytes than in granulocytes 
or monocytes (Supplemental Figure 4) [21, 22]. The 
aberrantly higher DNAm in PRDM8 was also reflected 
on lower gene expression level of PRDM8 in qRT-PCR 
analysis (Figure 2D). 
For site-specific analysis of DNAm at PRDM8 we 
designed pyrosequencing assays for the CpGs cg27242132 
(assay 1) and cg19409579 (assay 2). However, the 
measurements were susceptible for the annealing 
temperature in PCR (Supplemental Figure 5) and therefore 
we developed alternative assays based on MassARRAY 
(Figure 2E and 2F, Supplemental Figure 6). MassARRAY 
results were very similar to HumanMethylation450 
BeadChip data. Analysis of 11 DKC samples demonstrated 
significantly higher DNAm levels as compared to normal 
controls (P = 2.51E-06; Figure 2E and 2F). Notably, blood 
samples of 27 AA patients were also hypermethylated at 
this region (P = 1.49E-05), suggesting that DNAm in 
PRDM8 could serve as a new indicator for bone marrow 
failure syndromes. As cutoff for normal DNAm level at the 
CpG site cg27242132 we adopted the 99% percentile of 
the 4,131 DNAm profiles of normal blood, corresponding 
to a DNAm level of 52% (Figure 2D): Using this cutoff 
81.8% of the DKC (9 of 11) and 51.9% AA patients (14 of 
27) were identified as positive.
Subsequently, we correlated DNAm in PRDM8 
with telomere length measurements. All DKC patients 
revealed telomere length below the 1% percentile in 
lymphocytes, as measured by flow-FISH, because such 
telomere attrition has been used as criterion for DKC 
diagnosis. In contrast, only 7.4% of AA patients (2 of 27) 
were below this threshold (Figure 3). Similar results were 
observed for granulocytes (Supplemental Figure 7). There 
was no correlation between telomere length and DNAm 
in PRDM8. Thus, the two biomarkers are independent 
and can therefore be considered as complementary for 
diagnosis of both bone marrow syndromes, particularly 
for those patients that do not reveal significant telomere 
attrition. 
Aberrant hypermethylation in PRDM8 is indicative 
for DKC and AA, but it is not disease specific. Notably, 
it was also observed in Down syndrome (DS) - another 
disease associated with symptoms of premature aging 
(Supplemental Figure 8) [23]. Analysis in The Cancer 
Genome Atlas (TCGA) demonstrated that the relevant 
genomic region was generally higher methylated in tumor 
tissue (Supplemental Figure 9). We reasoned that DNAm 
at PRDM8 might be co-regulated with other genomic 
regions. Using 62 DNAm profiles of acute myeloid 
leukemia (AML) [24] we identified 151 CpGs showing 
Figure 3: DNAm in PRDM8 is indicative for DKC and AA. A. Telomere length of lymphocytes was measured by flow-FISH for 
114 healthy individuals (grey and blue) [12], 11 dyskeratosis congenital patients (DKC; red) and 27 patients with aplastic anemia (AA; 
yellow). B. Delta telomere length - in relation to age-adjusted mean telomere length in 104 healthy controls - revealed telomere attrition 
particularly in DKC patients (P = 3.07E-08), but overall also in AA patients (P = 0.0232). C. Delta telomere length was plotted against 
DNAm in PRDM8 for DKC and AA samples. Cutoffs for 1 percentile in telomere length and 99 percentile in DNAm of PRDM8 are 
indicated by areas shaded in blue.
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clear correlation with beta-values at cg27242132 (Pearson 
correlation: r > 0.60 or r < - 0.60). Among these several 
CpGs corresponded to PRDM16 indicating that the two 
functionally related genes might also be co-regulated on 
epigenetic level (Supplemental Figure 10) [25]. 
CONCLUSIONS
Age-associated DNAm patterns are not generally 
accelerated in blood of DKC patients. However, we 
demonstrate that specific genomic regions reveal aberrant 
DNAm patterns in this disease. Aberrant hypermethylation 
was particularly observed at an internal promoter region of 
PRDM8. Notably, aberrant hypermethylation at the very 
same genomic region was also observed in patients with 
AA or Down syndrome - and all of these diseases present 
clinical features of premature aging. DNAm changes are 
also reflected on gene expression level and this warrants 
further functional studies in the future on whether or not 
PRDM8 directly impacts on cellular aging. On the other 
hand, we provide simple and cost-effective assays for 
DNAm measurements in PRDM8 that are even applicable 
in unsorted peripheral blood. A variety of scoring systems 
based on TL in different cellular subsets have been 
proposed to improve diagnosis of AA and DKC [26], but 
it remains a challenge for patients without severe telomere 
attrition. DNAm in PRDM8 should be further analyzed in 
such subsets of patients, in additional cohorts, and other 
diseases to ultimately demonstrate the clinical potential as 
a new biomarker. 
MATERIALS AND METHODS
Samples of DKC and AA patients
Blood samples were obtained from the Registry 
for Telomeropathies and Aplastic Syndromes of RWTH 
Aachen University and participating hospitals (15 DKC 
patients and 32 AA patients). Furthermore, we used blood 
samples of 14 healthy individuals. The study was approved 
by the local ethic committee and all samples were taken 
after written consent (EK206/09). The DKC patients 
revealed TL below 1% percentile and diagnosis was 
complemented by clinical and genotypic characteristics 
(Supplemental Table 3). Clinical information about AA 
patients is provided in Supplemental Table 4. 
Next-generation sequencing of DKC patients
The genotype of four patients has already been 
published before [27-29]. For the other patients we 
utilized a multiplex-PCR approach (Truseq Amplicon, 
Illumina®) if enough DNA was available. To this end, we 
analyzed 158 amplicons covering 8 telomerase associated 
genes (NOP10, NHP2, CTC1, DKC1, TERT, TERC, TIN2, 
RTEL1). 250ng of genomic DNA of 9 DKC samples was 
prepared according to the TruSeq sample preparation 
guide. Sequencing data were analyzed using BaseSpace 
online analysis tool (Illumina, San Diego, CA, USA) 
and SeqPilot software (JSI medical systems, Ettenheim, 
Germany). To detect heterozygous or homozygous 
variants, conditions for scoring a mutant allele were: 
absolute coverage at SNV-Site ≥ 50 and relative allele 
burden of the variant ≥ 30% of all reads. Further analysis 
was performed using MutationTaster software (http://
www.mutationtaster.org) and PolyPhen-2 software 
(http://genetics.bwh.harvard.edu/pph2/bgi.shtml) 
to predict pathogenicity of detected variants. 
Telomere length measurement by flow-FISH
Telomere length was analyzed as described 
previously [12, 30, 31]. Measurements were performed 
in triplicates with and without Alexa488-(C3TA2) PNA 
(Panagene, South Korea). Cow thymocytes were used 
as an internal control to calculate telomere length in kilo 
bases (kb). Identification of lymphocytes, granulocytes 
and cow thymocytes was done based on forward scatter 
properties and LDS 751 fluorescence. Peripheral blood 
of 104 healthy controls was used as for age-adaption as 
described previously [12, 30]. 
DNA methylation profiles
Genomic DNA was isolated from four DKC patients 
with the QIAamp DNA Blood Midi Kit (Qiagen, Hilden, 
Germany; these samples are indicated in Supplemental 
Table 3). DNA quality was assessed with a NanoDrop 
ND-1000 spectrometer and by gel electrophoresis and 
then analyzed with the Illumina HumanMethylation450 
BeadChip (Illumina). This platform can assay more than 
480,000 CpG sites at single base resolution (covering 
99% of RefSeq genes and 96% of CpG islands) [32]. 
Hybridization and initial data analysis using the 
BeadStudio Methylation module was performed at the 
DKFZ Gene Core Facility (Heidelberg, Germany). Raw 
data are available at Gene Expression Omnibus under the 
accession number GSE75310. Beta-values ranging from 
0 (non-methylated) to 1 (100% methylation) are provided 
for each CpG site. 
In addition, we utilized the following publically 
available datasets of normal peripheral blood: GSE32148 
[33], GSE30870 [34], GSE36064 [35], GSE40005, 
GSE40279 [36], GSE41169 [37], GSE42861 [38], 
GSE50660 [39], GSE51180 [40], GSE51388, GSE56046 
[41], GSE56105 [42], GSE56581 [41], GSE58651 
[43], GSE61496 [44], GSE62992, and GSE49064 [45]. 
DNAm profiles of patients with Down syndrom were 
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retrieved from GSE52588 [23]. AML profiles were used 
from a dataset by Qu et al. (GSE58477) [24]. Additional 
DNAm values were downloaded from the UCSC Cancer 
Genomics Browser (www.genome-cancer.ucsc.edu/) for 
various types of cancer as indicated. Unpaired limma t-test 
was calculated in R to select for significantly changed 
CpG sites (adjusted P value < 0.05).
Pyrosequencing of PRDM8
Site-specific analysis of DNAm levels in PRDM8 
was analyzed for 14 controls, 13 DKC, and 20 AA samples. 
Primers were designed for two different regions (assay 
1 and assay 2). 100 ng of DNA was bisulfite converted 
using the EZ DNA Methylation Kit (Zymo, Irvine, CA, 
USA) and amplified by PCR with annealing temperatures 
of 56˚C and 65˚C, respectively. After amplification 
20 µl of the PCR product was immobilized to 5 µl of 
Streptavidin beads (GE Healthcare, Piscataway, NJ, USA) 
and annealed to 0.8 µl sequencing primer (20 µM) for 2 
min at 80˚C. For pyrosequencing the PyorMark Q96 ID 
system was utilized and analysis was performed with the 
PyroMark Q CpG software (Qiagen, Hilden, Germany). 
Primers: assay 1 forward: 5´-biotin-GGGGTTGTTT 
ATTGTTAGTA ATATTGTATA AAAGGAGGA-3´; 
assay 1 reverse: 5´-ACCCCGCTCT AAACCCAAAT 
TCTT-3´; assay 1 sequencing: 5´-GCCTACCCTA 
AAAATATACC-3´; assay 2 forward: 5´-AGTGAAACGG 
GGAAAGGTTT TTTTTAATTA TTTTGG-3´; assay 2 
reverse: 5´-biotin-GTCCCCTCCC TTTAACTCTT 
TACTAAACCA A-3´; assay 2 sequencing 
5´-TTTTGAGAGG CGTTGTTATT-3´.
MassArray of PRDM8
Alternatively, we used MassARRAY for site-
specific analysis of DNAm levels. This highly sensitive 
method is based on MALDI-TOF mass spectrometry 
and measurements were performed at Varionostic GmbH 
(www.varionostic.de; Ulm, Germany). Samples of 
10 healthy controls, 11 DKC, and 27 AA patients were 
analyzed. Amplicons were designed with the Sequenom's 
EpiDESIGNER software. 150 ng of DNA was bisulfite 
converted with the EZ DNA Methylation Gold Kit 
(Zymo). Converted DNA was amplified by PCR using the 
HotStart Plus PCR Master Mix (Qiagen). Unincorporated 
dNTPs were neutralized using shrimp alkaline phosphatase 
(Agena Bioscience, San Diego, CA, USA). Subsequently, 
10 µl of PCR product was in vitro transcribed and cleaved 
in a base-specific (U-specific) manner using RNase A 
(T-Cleavage MassCleave Kit; Agena Bioscience). The 
cleaved products were then analyzed by the MALDI-
TOF mass spectrometer. Mass differences of 16 Da 
or n-fold were representative for methylation events. 
The experiment was performed with a MassARRAY 
Analyzer 4 System (Agena Bioscience). Primers: assay 1 
forward: 5´-aggaagagag TTTTTGAGGG GTTGTTTATT 
GTTAGT-3´; assay 1 reverse: 5´-cagtaatacg actcactata 
gggagaaggc tTACCCTAAA AATATACCCC AAAACC-3´; 
assay 2 forward: 5´-aggaagagag GGGGAAAGGT 
TTTTTTTAAT TATTTT-3´; assay 2 reverse: 5´-cagtaatacg 
actcactata gggagaaggc tCCCTCCCTT TAACTCTTTA 
CTAAACC-3´ (Bases that correspond to the converted 
sequence of PRDM8 are indicated in capital letters).
qRT-PCR of PRDM8
Expression of PRDM8 was analyzed by real-time 
quantitative PCR (RT-qPCR) using the StepOneTM 
Instrument (Applied Biosystems, Applera Deutschland 
GmbH, Darmstadt, Germany). 250ng RNA was reverse-
transcribed using the high capacity cDNA Reverse 
Transcription Kit (Applied Biosystems). cDNA was 
amplified using Power SYBR Green PCR Master Mix 
(Applied Biosystems). Gene expression was normalized to 
GAPDH. The following primers (Metabion, Martinsried, 
Germany) were used for amplification of PRDM8: 
forward: 5´-ACCAGCGTTT ACACCACCTG-3´; reverse: 
5´-CCATTTGCTG CTGAGGTGTC-3´.
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